Welcome to our dedicated page for Iqvia Hldgs news (Ticker: IQV), a resource for investors and traders seeking the latest updates and insights on Iqvia Hldgs stock.
IQVIA Holdings Inc. (IQV) delivers integrated healthcare insights through its unique combination of clinical research expertise and advanced data analytics. This news hub provides investors and industry professionals with timely updates on corporate developments shaping the life sciences sector.
Access official press releases and curated news coverage spanning clinical trial milestones, healthcare data partnerships, regulatory updates, and technology innovations. Our collection serves as a strategic resource for understanding IQVIA's role in optimizing drug development cycles and commercial decision-making.
Key content categories include earnings announcements, merger/acquisition activity, leadership changes, and analytical breakthroughs in real-world evidence applications. Bookmark this page for efficient tracking of IQVIA's progress in transforming clinical research through data-driven solutions.
IQVIA (NYSE:IQV) announced a long-term collaboration with Clalit, Israel's largest health organization, to launch its first Prime Site in Israel. This partnership aims to enhance clinical trial delivery and real-world research through combined expertise in data analytics and genomics. Clalit, which operates 14 hospitals and over 1600 clinics, will utilize its Prime Site designation to provide patients with access to advanced therapies. The collaboration is expected to transform healthcare and pharmaceutical research, positioning Israel as a hub for innovation.
IQVIA Holdings Inc. reported Q3 2022 revenue of $3,562 million, up 5.0% year-over-year, achieving a GAAP net income of $283 million, an increase of 8.4%. Adjusted EBITDA rose 11.8% to $814 million. R&D Solutions booked over $2.5 billion in quarterly bookings, with a record $2.0 billion excluding pass-throughs, yielding a book-to-bill ratio of 1.39x. The contracted backlog reached $25.8 billion, up 5.4%. For FY 2022, revenue guidance is updated to $14.325-14.425 billion, reflecting growth despite macroeconomic challenges.
IQVIA Holdings Inc. (NYSE:IQV) announced that CFO Ron Bruehlman will present at the Credit Suisse Annual Healthcare Conference on November 8, 2022, at 12:10 p.m. ET in Rancho Palos Verdes. A live webcast of the event will be available on the IQVIA Investor Relations website, with a replay accessible later the same day. IQVIA is a global provider of analytics and technology solutions in the life sciences sector, employing around 83,000 people across over 100 countries, focusing on enhancing healthcare through innovative treatments.
Q² Solutions, a subsidiary of IQVIA, has launched the first self-collection safety lab panel for U.S. clinical trial participants. This service, developed with Tasso Inc, allows patients to collect blood samples at home, enhancing convenience and reducing the need for clinical visits. The initial panel monitors liver function through various enzyme and protein tests. Q² Solutions aims to expand this offering with over a dozen additional safety tests, emphasizing patient-centered design and logistics optimization.
IQVIA Holdings Inc. (NYSE:IQV) is set to announce its third-quarter 2022 financial results before the market opens on October 26, 2022. The management team will host a conference call at 9:00 a.m. ET on the same day, with details available on the IQVIA Investor Relations website. A replay of the webcast will be accessible about two hours after the event. IQVIA is a leader in analytics, technology solutions, and clinical research for life sciences, employing approximately 83,000 individuals in over 100 countries.
IQVIA (NYSE:IQV) announced its Decentralized Clinical Trial (DCT) program is the first to receive GDPR compliance validation from TRUSTArc, enhancing its commitment to data protection in Europe. This validation ensures that personal data in decentralized trials is processed in accordance with GDPR, addressing privacy concerns for participants. The achievement reinforces IQVIA's dedication to delivering decentralized studies while improving diversity and sustainability in clinical development, as emphasized by key executives.
IQVIA announced findings highlighting the benefits of decentralized clinical trials (DCT), demonstrating that they can lead to faster, cheaper, and more engaging trials compared to traditional methods.
The company provided tangible data on 14 metrics, revealing significant reductions in timelines and improved patient engagement. Notable metrics include faster timeframes from Final Protocol to First Patient In and decreased Screen Failure Rates. These insights provide valuable information for sponsors looking to optimize clinical trial designs.
IQVIA Holdings Inc. (NYSE:IQV) will have its chairman and CEO, Ari Bousbib, speak at the Baird 2022 Global Healthcare Conference in New York City on September 14, 2022, at 2:35 p.m. ET. Investors can access a live audio webcast via the IQVIA Investor Relations website, with a replay available later. IQVIA is a global leader in analytics and clinical research services, enhancing healthcare through innovative insights and technology with a workforce of approximately 82,000 across over 100 countries.
IQVIA Holdings Inc. (NYSE:IQV) will feature its CFO, Ron Bruehlman, at the Morgan Stanley Annual Global Healthcare Conference on September 13, 2022, at 11:10 a.m. ET in New York City. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website, with a replay accessible later that day. IQVIA is recognized for its analytics and clinical research services, employing approximately 82,000 individuals across over 100 countries.
